Evidence map›Paper›PMID 35140819›Full record

ArticleDisease markers2022

Comprehensive Analysis of

Bingli Qi, Shikai Liu, Dantong Liu, Hairong Yao, Ruixue Yan

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bingli QiDepartment III of Gynecology, Cangzhou Central Hospital, Cangzhou, China.ORCID https://orcid.org/0000-0003-2873-7461
Shikai LiuDepartment III of Gynecology, Cangzhou Central Hospital, Cangzhou, China.
Dantong LiuDepartment III of Gynecology, Cangzhou Central Hospital, Cangzhou, China.
Hairong YaoDepartment III of Gynecology, Cangzhou Central Hospital, Cangzhou, China.
Ruixue YanDepartment I of Gynecology, Cangzhou Central Hospital, Cangzhou, China.
Cangzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the development of sequencing technology, an increasing number of biomarkers have been identified in ovarian cancer (OC). However, there have been few comprehensive analyses of

methodsLogistic regression analysis was conducted to analyze the correlations between clinical characteristics and

resultsThe overexpression of

conclusionWe provided robust evidences that

Indexed as

Gene Regulatory NetworksCarrier ProteinsCell Line, TumorFemaleHumansLIM Domain ProteinsMiddle AgedOvarian NeoplasmsRNACarrier ProteinsCRIP1 protein, humanLIM Domain ProteinsRNA

Identifiers

PMID35140819
PMCPMC8820892
OpenAlexW4213270738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.